Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26895ArticlesСтатьиResearch ArticleAntiangiogennaya terapiya disseminirovannogo kolorektal'nogo rakaАнтиангиогенная терапия диссеминированного колоректального ракаMeshcheryakovAndrey Al'bertovichМещеряковАндрей Альбертович

д-р мед. наук

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва15092013153VOL 15, NO3 (2013)ТОМ 15, №3 (2013)121509042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26895

Ангиогенез играет ключевую роль в развитии, инвазии и метастазировании колоректального рака. Преобладающим медиатором ангиогенеза опухоли является фактор роста эндотелия сосудов. Другие факторы роста, участвующие в ангиогенезе колоректального рака, включают фактор роста фибробластов, трансформирующий фактор роста-a, эпидермальный фактор роста и тромбоцитарный фактор роста. Ингибиторы ангиогенеза, такие как бевацизумаб, афлиберцепт и регорафениб, блокируют опухолевый ангиогенез и используются в лечении колоректального рака.

колоректальный ракангиогенезбевацизумабафлиберцептрегорафенибBennouna J, Sastre J, Arnold D et al. on behalf of the ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. www.thelancet.com/oncology; http://dx.doi.org/10.1016/S1470-2045(12)70477-1Ferrara N et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391–400.Fuchs C.S, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first - line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779–86.Giantonio B.J, Catalano P.J, Meropol N.J et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44.Grothey A, Sobrero A. Results of a phase III randomized, double - blind, placebocontrolled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 2012; 30. Аbstr. LBA 385.Hicklin D.J, Ellis L.M. Role of the vascular endothelial growth factor pathway in the tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–27.Hochster H.S, Hart L.L, Ramanathan R.K et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first - line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523–9.Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.Kabbinavar F.F, Schulz J, Mc Cleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first - line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705.Saltz L.B, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin - based chemotherapy as first - line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013–9.Schmoll H, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–516.Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549–60.Tebbutt N.C, Wilson K, Gebski V.J et al. Capecitabine, bevacizumab, and mitomycin in first - line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol 2010; 28: 3191–8.Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin - based regimen. http://jco.ascopubs.org/cgi/ doi/10.1200/JCO.2012.42.8201